[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651885":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":26,"collaborators":28,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":45,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":54,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":10},{"fullName":5,"class":6},"D'Or Institute for Research and Education","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"At-Risk Patients Under Structured HCC Surveillance",null,"Adult participants at increased risk of hepatocellular carcinoma, including patients with cirrhosis, chronic hepatitis B, advanced fibrosis, or metabolic dysfunction-associated steatotic liver disease, enrolled in a structured surveillance program consisting of semiannual ultrasound using US LI-RADS and alpha-fetoprotein assessment as part of routine clinical care.",[13],{"name":14,"affiliation":15,"role":16},"Leonardo G Fonseca, MD, MSc","D'Or Institute for Research and Education (IDOR)","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Guilherme C Ambrósio, MSc","CONTACT","+55 11 972763211","guilherme.ambrosio@idor.org",{"name":24,"role":20,"phone":10,"phoneExt":10,"email":25},"Escritório O Operações","gestao.ensaiosclinicos@idor.org",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[29],{"name":30,"class":31},"AstraZeneca","INDUSTRY","100651885","prospective-evaluation-of-hepatocellular-carcinoma-surveillance-in-at-risk-patients-screening-hcc-100651885",false,"NCT07764835","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients Using Semiannual Ultrasound LI-RADS and Alpha-Fetoprotein: A Multicenter Real-World Observational Study","Screening HCC","Inclusion Criteria:\n\n* Written informed consent.\n* Age 18 years or older.\n* Liver cirrhosis of any etiology.\n* Chronic hepatitis B with moderate or high risk of HCC according to PAGE-B criteria.\n* Non-cirrhotic chronic liver disease with increased risk for HCC, including fibrosis stage 3 or higher or metabolic dysfunction-associated steatotic liver disease (MASLD) with one or more risk factors for HCC.\n* Followed at hepatology clinics within the Rede D'Or health network.\n* Eligible for routine HCC surveillance with ultrasound and alpha-fetoprotein according to standard clinical practice.\n\nExclusion Criteria:\n\n* Known hepatocellular carcinoma at enrollment.\n* Previous diagnosis of hepatocellular carcinoma.\n* Metastatic liver disease.\n* Other malignant liver tumors present at enrollment.\n* Clinical condition preventing routine surveillance follow-up.\n* Inability to provide informed consent.","ALL","18 Years",{"count":43,"type":44},300,"ESTIMATED","36 Months","OBSERVATIONAL","This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer. Participants will undergo routine surveillance with semiannual abdominal ultrasound reported using the Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) and serum alpha-fetoprotein (AFP) testing as part of standard clinical care. The study aims to assess HCC detection rates, stage at diagnosis, detection of other hepatic malignancies, and the time intervals between detection, diagnosis, and treatment in a real-world setting. Approximately 300 participants will be enrolled and followed for up to 36 months.",[49,50,51,52,53],"Hepatocellular Carcinoma","Liver Cirrhosis","Chronic Hepatitis B","Metabolic Dysfunction-Associated Steatotic Liver Disease","Advanced Liver Fibrosis",[55,49,56,57,58,59,60,61,50,51,62,52,63,64,65,66,67,68],"HCC","Liver Cancer","HCC Surveillance","US LI-RADS","Ultrasound LI-RADS","Alpha-Fetoprotein","AFP","MASLD","Real-World Study","Observational Study","Early Detection","BCLC","Rede D'Or","Brazil","NOT_YET_RECRUITING","2026-08-10",{"date":72,"type":73},"2026-08-14","ACTUAL",{"date":75,"type":44},"2026-09-15",{"date":77,"type":44},"2029-06-30",{"name":5,"class":6}]